Emerging immunotherapeutic strategies for cutaneous lupus erythematosus: an overview of recent phase 2 and 3 clinical trials

References

• Gronhagen CM, Fored CM, Granath F, et al. Cutaneous lupus erythematosus and the association with systemic lupus erythematosus: a population-based cohort of 1088 patients in Sweden. Br J Dermatol. 2011 Jun;164(6):1335–1341. 10.1111/j.1365-2133.2011.10272.x
   PubMed Web of Science ®Google Scholar
• Okon LG, Werth VP Cutaneous lupus erythematosus: diagnosis and treatment. Best Pract Res Clin Rheumatol. 2013 Jun;27(3):391–404. 10.1016/j.berh.2013.07.008
   PubMed Web of Science ®Google Scholar
• Gilliam JN, Sontheimer RD. Distinctive cutaneous subsets in the spectrum of lupus erythematosus. J Am Acad Dermatol. 1981 Apr;4(4):471–475. doi: 10.1016/S0190-9622(81)80261-7
   PubMed Web of Science ®Google Scholar
• Watanabe T, Tsuchida T. Classification of lupus erythematosus based upon cutaneous manifestations. Dermatological, systemic and laboratory findings in 191 patients. Dermatology. 1995;190(4):277–283. doi: 10.1159/000246716
   PubMed Web of Science ®Google Scholar
• Kuhn A, Landmann A. The classification and diagnosis of cutaneous lupus erythematosus. J Autoimmun. 2014 Feb;48-49:14–19. doi: 10.1016/j.jaut.2014.01.021
   PubMed Web of Science ®Google Scholar
• Stull C, Sprow G, Werth VP Cutaneous involvement in systemic lupus erythematosus: a review for the rheumatologist. J Rheumatol. 2023 Jan;50(1):27–35.10.3899/jrheum.220089
   PubMed Web of Science ®Google Scholar
• Elman SA, Joyce C, Braudis K, et al. Creation and validation of classification criteria for discoid lupus erythematosus. JAMA Dermatol. 2020 Aug 1;156(8):901–906. 10.1001/jamadermatol.2020.1698
   PubMed Web of Science ®Google Scholar
• Durosaro O, Davis MD, Reed KB, et al. Incidence of cutaneous lupus erythematosus, 1965-2005: a population-based study. Arch Dermatol. 2009 Mar;145(3):249–253. 10.1001/archdermatol.2009.21
   PubMedGoogle Scholar
• Petersen MP, Moller S, Bygum A, et al. Epidemiology of cutaneous lupus erythematosus and the associated risk of systemic lupus erythematosus: a nationwide cohort study in Denmark. Lupus. 2018 Aug;27(9):1424–1430.10.1177/0961203318777103
   PubMed Web of Science ®Google Scholar
• Drenkard C, Parker S, Aspey LD, et al. Racial disparities in the incidence of primary chronic cutaneous lupus erythematosus in the Southeastern US: the Georgia lupus registry. Arthritis Care Res (Hoboken). 2019 Jan;71(1):95–103. 10.1002/acr.23578
   PubMed Web of Science ®Google Scholar
• Curtiss P, Walker AM, Chong BF. A systematic review of the progression of cutaneous lupus to systemic lupus erythematosus. Front Immunol. 2022;13:866319. doi: 10.3389/fimmu.2022.866319
   PubMed Web of Science ®Google Scholar
• Klein R, Moghadam-Kia S, Taylor L, et al. Quality of life in cutaneous lupus erythematosus. J Am Acad Dermatol. 2011 May;64(5):849–858. 10.1016/j.jaad.2010.02.008
   PubMed Web of Science ®Google Scholar
• Hesselvig JH, Egeberg A, Kofoed K, et al. Increased risk of depression in patients with cutaneous lupus erythematosus and systemic lupus erythematosus: a Danish nationwide cohort study. Br J Dermatol. 2018 Nov;179(5):1095–1101.10.1111/bjd.16831
   PubMed Web of Science ®Google Scholar
• Drenkard C, Barbour KE, Greenlund KJ, et al. The burden of living with cutaneous lupus erythematosus. Front Med. 2022;9:897987. doi: 10.3389/fmed.2022.897987
   Web of Science ®Google Scholar
• Ogunsanya ME, Brown CM, Lin D, et al. Understanding the disease burden and unmet needs among patients with cutaneous lupus erythematosus: a qualitative study. Int J Womens Dermatol. 2018 Sep;4(3):152–158. 10.1016/j.ijwd.2018.01.002
   PubMedGoogle Scholar
• Yan D, Zamalin D, Chakka S, et al. Cutaneous lupus concerns from the patient perspective: a qualitative study. Lupus Sci Med. 2021 Aug;8(1). e000444 10.1136/lupus-2020-000444
   PubMed Web of Science ®Google Scholar
• Wenzel J Cutaneous lupus erythematosus: new insights into pathogenesis and therapeutic strategies. Nat Rev Rheumatol. 2019 Sep;15(9):519–532.10.1038/s41584-019-0272-0
   PubMed Web of Science ®Google Scholar
• Achtman JC, Werth VP. Pathophysiology of cutaneous lupus erythematosus. Arthritis Res Ther. 2015 Aug 10;17(1):182.
   PubMed Web of Science ®Google Scholar
• Patel J, Vazquez T, Chin F, et al. Multidimensional immune profiling of cutaneous lupus erythematosus in vivo stratified by patient response to Antimalarials. Arthritis & Rheumat. 2022 Oct;74(10):1687–1698. 10.1002/art.42235
   PubMed Web of Science ®Google Scholar
• Billi AC, Ma F, Plazyo O, et al. Nonlesional lupus skin contributes to inflammatory education of myeloid cells and primes for cutaneous inflammation. Sci Transl Med. 2022 Apr 27;14(642):eabn2263. doi: 10.1126/scitranslmed.abn2263
   PubMed Web of Science ®Google Scholar
• Albrecht J, Werth VP Development of the CLASI as an outcome instrument for cutaneous lupus erythematosus. Dermatol Ther. 2007 Mar;20(2):93–101.10.1111/j.1529-8019.2007.00117.x
   PubMed Web of Science ®Google Scholar
• Albrecht J, Taylor L, Berlin JA, et al. The CLASI (cutaneous lupus erythematosus disease Area and severity index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol. 2005 Nov;125(5):889–894. doi: 10.1111/j.0022-202X.2005.23889.x.
   PubMed Web of Science ®Google Scholar
• Werth VP, Furie RA, Romero-Diaz J, et al. Trial of anti-BDCA2 antibody litifilimab for cutaneous lupus erythematosus. N Engl J Med. 2022 Jul 28;387(4):321–331. doi: 10.1056/NEJMoa2118024
   PubMed Web of Science ®Google Scholar
• Chakka S, Krain RL, Ahmed S, et al. Evaluating change in disease activity needed to reflect meaningful improvement in quality of life for clinical trials in cutaneous lupus erythematosus. J Am Acad Dermatol. 2021 Jun;84(6):1562–1567. 10.1016/j.jaad.2020.07.047
   PubMed Web of Science ®Google Scholar
• Borucki R, Werth VP Expert perspective: an Evidence-based approach to refractory cutaneous lupus erythematosus. Arthritis & rheumat. 2020 Nov;72(11):1777–1785. 10.1002/art.41480
   PubMed Web of Science ®Google Scholar
• Shi H, Gudjonsson JE, Kahlenberg JM Treatment of cutaneous lupus erythematosus: current approaches and future strategies. Curr Opin Rheumatol. 2020 May;32(3):208–214. 10.1097/BOR.0000000000000704
   PubMed Web of Science ®Google Scholar
• Chasset F, Frances C Current concepts and future approaches in the treatment of cutaneous lupus erythematosus: a comprehensive review. Drugs. 2019 Jul;79(11):1199–1215.10.1007/s40265-019-01151-8
   PubMed Web of Science ®Google Scholar
• Kuhn A, Ruland V, Bonsmann G Photosensitivity, phototesting, and photoprotection in cutaneous lupus erythematosus. Lupus. 2010 Aug;19(9):1036–1046.10.1177/0961203310370344
   PubMed Web of Science ®Google Scholar
• Herzinger T, Plewig G, Rocken M Use of sunscreens to protect against ultraviolet-induced lupus erythematosus. Arthritis Rheum. 2004 Sep;50(9):3045–3046. 10.1002/art.20426
   PubMedGoogle Scholar
• Stege H, Budde MA, Grether-Beck S, et al. Evaluation of the capacity of sunscreens to photoprotect lupus erythematosus patients by employing the photoprovocation test. Photodermatol Photoimmunol Photomed. 2000 Dec;16(6):256–259. 10.1034/j.1600-0781.2000.160604.x
   PubMed Web of Science ®Google Scholar
• Turchin I, Bernatsky S, Clarke AE, et al. Cigarette smoking and cutaneous damage in systemic lupus erythematosus. J Rheumatol. 2009 Dec;36(12):2691–2693. 10.3899/jrheum.090403
   PubMed Web of Science ®Google Scholar
• Piette EW, Foering KP, Chang AY, et al. Impact of smoking in cutaneous lupus erythematosus. Arch Dermatol. 2012 Mar;148(3):317–322. 10.1001/archdermatol.2011.342
   PubMedGoogle Scholar
• Chasset F, Frances C, Barete S, et al. Influence of smoking on the efficacy of antimalarials in cutaneous lupus: a meta-analysis of the literature. J Am Acad Dermatol. 2015 Apr;72(4):634–639. 10.1016/j.jaad.2014.12.025
   PubMed Web of Science ®Google Scholar
• Kuhn A, Aberer E, Bata-Csorgo Z, et al. S2k guideline for treatment of cutaneous lupus erythematosus - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and venereology (EADV). J Eur Acad Dermatol Venereol. 2017 Mar;31(3):389–404. 10.1111/jdv.14053
   PubMed Web of Science ®Google Scholar
• Fairley JL, Oon S, Saracino AM, et al. Management of cutaneous manifestations of lupus erythematosus: a systematic review. Semin Arthritis Rheum. 2020 Feb;50(1):95–127. doi: 10.1016/j.semarthrit.2019.07.010
   PubMed Web of Science ®Google Scholar
• James JA, Kim-Howard XR, Bruner BF, et al. Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus. Lupus. 2007;16(6):401–409. doi: 10.1177/0961203307078579
   PubMed Web of Science ®Google Scholar
• Yokogawa N, Eto H, Tanikawa A, et al. Effects of hydroxychloroquine in patients with cutaneous lupus erythematosus: a multicenter, double-blind, randomized, parallel-group trial. Arthritis & rheumat. 2017 Apr;69(4):791–799. 10.1002/art.40018
   PubMed Web of Science ®Google Scholar
• Shipman WD, Vernice NA, Demetres M, et al. An update on the use of hydroxychloroquine in cutaneous lupus erythematosus: a systematic review. J Am Acad Dermatol. 2020 Mar;82(3):709–722. 10.1016/j.jaad.2019.07.027
   PubMed Web of Science ®Google Scholar
• Mittal L, Zhang L, Feng R, et al. Antimalarial drug toxicities in patients with cutaneous lupus and dermatomyositis: a retrospective cohort study. J Am Acad Dermatol. 2018 Jan;78(1):100–106 e1. 10.1016/j.jaad.2017.09.061
   PubMed Web of Science ®Google Scholar
• O’Kane D, McCourt C, Meggitt S, et al. British Association of Dermatologists guidelines for the management of people with cutaneous lupus erythematosus 2021. Br J Dermatol. 2021 Dec;185(6):1112–1123.10.1111/bjd.20597
   PubMed Web of Science ®Google Scholar
• Islam MN, Hossain M, Haq SA, et al. Efficacy and safety of methotrexate in articular and cutaneous manifestations of systemic lupus erythematosus. Int J Of Rheum Dis. 2012 Feb;15(1):62–68. 10.1111/j.1756-185X.2011.01665.x
   PubMed Web of Science ®Google Scholar
• Wenzel J, Brahler S, Bauer R, et al. Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients. Br J Dermatol. 2005 Jul;153(1):157–162.10.1111/j.1365-2133.2005.06552.x
   PubMed Web of Science ®Google Scholar
• Boehm IB, Boehm GA, Bauer R. Management of cutaneous lupus erythematosus with low-dose methotrexate: indication for modulation of inflammatory mechanisms. Rheumatol Int. 1998;18(2):59–62. doi: 10.1007/s002960050058
   PubMed Web of Science ®Google Scholar
• Sigges J, Biazar C, Landmann A, et al. Therapeutic strategies evaluated by the European Society of cutaneous lupus erythematosus (EUSCLE) core set questionnaire in more than 1000 patients with cutaneous lupus erythematosus. Autoimmun Rev. 2013 May;12(7):694–702. 10.1016/j.autrev.2012.10.005
   PubMed Web of Science ®Google Scholar
• Fruchter R, Kurtzman DJB, Patel M, et al. Characteristics and alternative treatment outcomes of antimalarial-refractory cutaneous lupus erythematosus. JAMA Dermatol. 2017 Sep 1;153(9):937–939.10.1001/jamadermatol.2017.1160
   PubMed Web of Science ®Google Scholar
• Verdelli A, Corra A, Mariotti EB, et al. An update on the management of refractory cutaneous lupus erythematosus. Front Med. 2022;9:941003. doi: 10.3389/fmed.2022.941003
   PubMed Web of Science ®Google Scholar
• Hanjani NM, Nousari CH Mycophenolate mofetil for the treatment of cutaneous lupus erythematosus with smoldering systemic involvement. Arch Dermatol. 2002 Dec;138(12):1616–1618. 10.1001/archderm.138.12.1616
   PubMedGoogle Scholar
• Gammon B, Hansen C, Costner MI Efficacy of mycophenolate mofetil in antimalarial-resistant cutaneous lupus erythematosus. J Am Acad Dermatol. 2011 Oct;65(4):717–721 e2. 10.1016/j.jaad.2010.08.011
   PubMed Web of Science ®Google Scholar
• Keyes E, Jobanputra A, Feng R, et al. Comparative responsiveness of cutaneous lupus erythematosus patients to methotrexate and mycophenolate mofetil: a cohort study. J Am Acad Dermatol. 2022 Aug;87(2):447–448. 10.1016/j.jaad.2021.09.017
   PubMed Web of Science ®Google Scholar
• Kreuter A, Tomi NS, Weiner SM, et al. Mycophenolate sodium for subacute cutaneous lupus erythematosus resistant to standard therapy. Br J Dermatol. 2007 Jun;156(6):1321–1327.10.1111/j.1365-2133.2007.07826.x
   PubMed Web of Science ®Google Scholar
• Klebes M, Wutte N, Aberer E. Dapsone as second-line treatment for cutaneous lupus erythematosus? A retrospective analysis of 34 patients and a review of the literature. Dermatology. 2016;232(1):91–96. doi: 10.1159/000441054
   PubMed Web of Science ®Google Scholar
• Chang AY, Werth VP Treatment of cutaneous lupus. Curr Rheumatol Rep. 2011 Aug;13(4):300–307.10.1007/s11926-011-0180-z
   PubMed Web of Science ®Google Scholar
• Ruzicka T, Sommerburg C, Goerz G, et al. Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. Br J Dermatol. 1992 Nov;127(5):513–518.10.1111/j.1365-2133.1992.tb14851.x
   PubMed Web of Science ®Google Scholar
• Shornick JK, Formica N, Parke AL Isotretinoin for refractory lupus erythematosus. J Am Acad Dermatol. 1991 Jan;24(1):49–52. 10.1016/0190-9622(91)70008-P
   PubMed Web of Science ®Google Scholar
• Nesher G, Zuckner J Rheumatologic complications of vitamin a and retinoids. Semin Arthritis Rheum. 1995 Feb;24(4):291–296. 10.1016/S0049-0172(95)80039-5
   PubMed Web of Science ®Google Scholar
• Cortés-Hernández J, Torres-Salido M, Castro-Marrero J, et al. Thalidomide in the treatment of refractory cutaneous lupus erythematosus: prognostic factors of clinical outcome. Br J Dermatol. 2012 Mar;166(3):616–623. 10.1111/j.1365-2133.2011.10693.x
   PubMed Web of Science ®Google Scholar
• Ordi-Ros J, Cortés F, Cucurull E, et al. Thalidomide in the treatment of cutaneous lupus refractory to conventional therapy. J Rheumatol. 2000 Jun;27(6):1429–1433.
   PubMed Web of Science ®Google Scholar
• Kyriakis KP, Kontochristopoulos GJ, Panteleos DN Experience with low-dose thalidomide therapy in chronic discoid lupus erythematosus. Int J Dermatol. 2000 Mar;39(3):218–222.10.1046/j.1365-4362.2000.00953.x
   PubMed Web of Science ®Google Scholar
• Duong DJ, Spigel GT, Moxley RT 3rd, et al. American experience with low-dose thalidomide therapy for severe cutaneous lupus erythematosus. Arch Dermatol. 1999 Sep;135(9):1079–1087.10.1001/archderm.135.9.1079
   PubMedGoogle Scholar
• Cesbron E, Bessis D, Jachiet M, et al. Risk of thromboembolic events in patients treated with thalidomide for cutaneous lupus erythematosus: a multicenter retrospective study. J Am Acad Dermatol. 2018 Jul;79(1):162–165. 10.1016/j.jaad.2018.02.049
   PubMed Web of Science ®Google Scholar
• Briani C, Zara G, Rondinone R, et al. Positive and negative effects of thalidomide on refractory cutaneous lupus erythematosus. Autoimmunity. 2005 Nov;38(7):549–555.10.1080/08916930500285790
   PubMed Web of Science ®Google Scholar
• Cuadrado MJ, Karim Y, Sanna G, et al. Thalidomide for the treatment of resistant cutaneous lupus: efficacy and safety of different therapeutic regimens. Am J Med. 2005 Mar;118(3):246–250. 10.1016/j.amjmed.2004.04.030
   PubMed Web of Science ®Google Scholar
• Cortés-Hernández J, Ávila G, Vilardell-Tarrés M, et al. Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus. Arthritis Res Ther. 2012 Dec 7;14(6):R265. doi: 10.1186/ar4111
   PubMed Web of Science ®Google Scholar
• Okon L, Rosenbach M, Krathen M, et al. Lenalidomide in treatment-refractory cutaneous lupus erythematosus: efficacy and safety in a 52-week trial. J Am Acad Dermatol. 2014 Mar;70(3):583–584. 10.1016/j.jaad.2013.11.007
   PubMed Web of Science ®Google Scholar
• Fennira F, Chasset F, Soubrier M, et al. Lenalidomide for refractory chronic and subacute cutaneous lupus erythematosus: 16 patients. J Am Acad Dermatol. 2016 Jun;74(6):1248–1251. 10.1016/j.jaad.2016.01.054
   PubMed Web of Science ®Google Scholar
• Kindle SA, Wetter DA, Davis MD, et al. Lenalidomide treatment of cutaneous lupus erythematosus: the mayo clinic experience. Int J Dermatol. 2016 Aug;55(8):e431–9. 10.1111/ijd.13226
   PubMed Web of Science ®Google Scholar
• Vital EM, Wittmann M, Edward S, et al. Brief report: responses to rituximab suggest B cell-independent inflammation in cutaneous systemic lupus erythematosus. Arthritis & Rheumat. 2015 Jun;67(6):1586–1591. 10.1002/art.39085
   PubMed Web of Science ®Google Scholar
• Quelhas da Costa R, Aguirre-Alastuey ME, Isenberg DA, et al. Assessment of response to B-Cell depletion using rituximab in cutaneous lupus erythematosus. JAMA Dermatol. 2018 Dec 1;154(12):1432–1440. 10.1001/jamadermatol.2018.3793
   PubMed Web of Science ®Google Scholar
• Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010 Jan;62(1):222–233.10.1002/art.27233
   PubMed Web of Science ®Google Scholar
• Lu Q, Long H, Chow S, et al. Guideline for the diagnosis, treatment and long-term management of cutaneous lupus erythematosus. J Autoimmun. 2021 Sep;123:102707.
   PubMed Web of Science ®Google Scholar
• Kneeland R, Montes D, Endo J, et al. Improvement in cutaneous lupus erythematosus after twenty weeks of belimumab use: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2022 Nov;75(8):1838–1848.
   PubMedGoogle Scholar
• Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011 Dec;63(12):3918–3930. 10.1002/art.30613
   PubMed Web of Science ®Google Scholar
• Navarra SV, Guzman RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011 Feb 26;377(9767):721–731. doi: 10.1016/S0140-6736(10)61354-2
   PubMed Web of Science ®Google Scholar
• Stohl W, Schwarting A, Okada M, et al. Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week randomized, double-blind, placebo-controlled study. Arthritis & Rheumat. 2017 May;69(5):1016–1027. 10.1002/art.40049
   PubMed Web of Science ®Google Scholar
• Zhang F, Bae SC, Bass D, et al. A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea. Ann Rheum Dis. 2018 Mar;77(3):355–363.10.1136/annrheumdis-2017-211631
   PubMed Web of Science ®Google Scholar
• Patel J, Borucki R, Werth VP. An update on the pathogenesis of cutaneous lupus erythematosus and its role in clinical practice. Curr Rheumatol Rep. 2020 Aug 26;22(10):69. doi: 10.1007/s11926-020-00946-z.
   PubMed Web of Science ®Google Scholar
• Zeidi M, Kim HJ, Werth VP Increased myeloid dendritic cells and TNF-α expression predicts poor response to hydroxychloroquine in cutaneous lupus erythematosus. J Invest Dermatol. 2019 Feb;139(2):324–332. 10.1016/j.jid.2018.07.041
   PubMed Web of Science ®Google Scholar
• Crow MK, Olferiev M, Kirou KA. Type I interferons in autoimmune disease. Annu Rev Pathol. 2019 Jan 24;14(1):369–393.
   PubMedGoogle Scholar
• Sarkar MK, Hile GA, Tsoi LC, et al. Photosensitivity and type I IFN responses in cutaneous lupus are driven by epidermal-derived interferon kappa. Ann Rheum Dis. 2018 Nov;77(11):1653–1664.10.1136/annrheumdis-2018-213197
   PubMed Web of Science ®Google Scholar
• Lee AJ, Ashkar AA. The Dual nature of type I and type II interferons. Front Immunol. 2018;9:2061. doi: 10.3389/fimmu.2018.02061
   PubMed Web of Science ®Google Scholar
• Braunstein I, Klein R, Okawa J, et al. The interferon-regulated gene signature is elevated in subacute cutaneous lupus erythematosus and discoid lupus erythematosus and correlates with the cutaneous lupus area and severity index score. Br J Dermatol. 2012 May;166(5):971–975. doi: 10.1111/j.1365-2133.2012.10825.x
   PubMed Web of Science ®Google Scholar
• Berthier CC, Tsoi LC, Reed TJ, et al. Molecular profiling of cutaneous lupus lesions identifies subgroups distinct from clinical phenotypes. J Clin Med. 2019 Aug 17;8(8):1244. doi: 10.3390/jcm8081244
   PubMed Web of Science ®Google Scholar
• Wenzel J, Zahn S, Mikus S, et al. The expression pattern of interferon-inducible proteins reflects the characteristic histological distribution of infiltrating immune cells in different cutaneous lupus erythematosus subsets. Br J Dermatol. 2007 Oct;157(4):752–757. doi: 10.1111/j.1365-2133.2007.08137.x
   PubMed Web of Science ®Google Scholar
• Wenzel J, Uerlich M, Wörrenkämper E, et al. Scarring skin lesions of discoid lupus erythematosus are characterized by high numbers of skin-homing cytotoxic lymphocytes associated with strong expression of the type I interferon-induced protein MxA. Br J Dermatol. 2005 Nov;153(5):1011–1015.10.1111/j.1365-2133.2005.06784.x
   PubMed Web of Science ®Google Scholar
• Blomberg S, Eloranta ML, Cederblad B, et al. Presence of cutaneous interferon-alpha producing cells in patients with systemic lupus erythematosus. Lupus. 2001;10(7):484–490. doi: 10.1191/096120301678416042
   PubMed Web of Science ®Google Scholar
• Farkas L, Beiske K, Lund-Johansen F, et al. Plasmacytoid dendritic cells (natural interferon- alpha/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am J Pathol. 2001 Jul;159(1):237–243. 10.1016/S0002-9440(10)61689-6
   PubMed Web of Science ®Google Scholar
• Karnell JL, Wu Y, Mittereder N, et al. Depleting plasmacytoid dendritic cells reduces local type I interferon responses and disease activity in patients with cutaneous lupus. Sci Transl Med. 2021 May 26;13(595): doi: 10.1126/scitranslmed.abf8442
   PubMed Web of Science ®Google Scholar
• Pellerin A, Otero K, Czerkowicz JM, et al. Anti-BDCA2 monoclonal antibody inhibits plasmacytoid dendritic cell activation through Fc-dependent and Fc-independent mechanisms. EMBO Mol Med. 2015 Apr;7(4):464–476.10.15252/emmm.201404719
   PubMed Web of Science ®Google Scholar
• Gardet A, Pellerin A, McCarl CA, et al. Effect of in vivo hydroxychloroquine and ex vivo anti-BDCA2 mAb treatment on pDC IFNα production from patients affected with cutaneous lupus erythematosus. Front Immunol. 2019;10:275. doi: 10.3389/fimmu.2019.00275
   PubMed Web of Science ®Google Scholar
• Vazquez T, Kodali N, Diaz D, et al. 803 Plasmacytoid dendritic cells are not major producers of type 1 interferons in cutaneous lupus. Lupus Science & Medicine. 2022;9(Suppl 3):A56–A59.
   Google Scholar
• Samuel C, Cornman H, Kambala A, et al. A review on the safety of using JAK inhibitors in Dermatology: clinical and laboratory monitoring. Dermatol Ther (Heidelb). 2023 Mar;13(3):729–749. doi: 10.1007/s13555-023-00892-5
   PubMed Web of Science ®Google Scholar
• Miot HA, Criado PR, de Castro CCS, et al. JAK-STAT pathway inhibitors in dermatology. An Bras Dermatol. 2023 May 23;98(5):656–677. doi: 10.1016/j.abd.2023.03.001
   PubMed Web of Science ®Google Scholar
• Flier J, Boorsma DM, van Beek PJ, et al. Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation. J Pathol. 2001 Aug;194(4):398–405. 10.1002/1096-9896(200108)194:4<397:AID-PATH899>3.0.CO;2-S
   PubMed Web of Science ®Google Scholar
• Wenzel J, Wörenkämper E, Freutel S, et al. Enhanced type I interferon signalling promotes Th1-biased inflammation in cutaneous lupus erythematosus. J Pathol. 2005 Mar;205(4):435–442. 10.1002/path.1721
   PubMed Web of Science ®Google Scholar
• Riggs JM, Hanna RN, Rajan B, et al. Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus. Lupus Sci Med. 2018;5(1):e000261. doi: 10.1136/lupus-2018-000261
   PubMed Web of Science ®Google Scholar
• Furie R, Khamashta M, Merrill JT, et al. Anifrolumab, an anti-interferon-α receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis & Rheumat. 2017 Feb;69(2):376–386. 10.1002/art.39962
   PubMed Web of Science ®Google Scholar
• Furie RAM EF, Bruce IN, Manzi S, et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheumatol. 2019;1(4):e208–e219. doi: 10.1016/S2665-9913(19)30076-1
   Google Scholar
• Morand EF, Furie R, Tanaka Y, et al. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020 Jan 16;382(3):211–221. doi: 10.1056/NEJMoa1912196
   PubMed Web of Science ®Google Scholar
• Bruce IN, van Vollenhoven RF, Psachoulia K, et al. Time to onset of clinical response to anifrolumab in patients with SLE: pooled data from the phase III TULIP-1 and TULIP-2 trials. Lupus Sci Med. 2023 Jan;10(1). e000761 10.1136/lupus-2022-000761
   PubMed Web of Science ®Google Scholar
• Tummala R, Abreu G, Pineda L, et al. Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials. Lupus Sci Med. 2021 Feb;8(1). e000464 10.1136/lupus-2020-000464
   PubMed Web of Science ®Google Scholar
• Chasset F, Jaume L, Mathian A, et al. Rapid efficacy of anifrolumab in refractory cutaneous lupus erythematosus. J Am Acad Dermatol. 2023 Jul;89(1):171–173. 10.1016/j.jaad.2023.02.044
   PubMed Web of Science ®Google Scholar
• Carter LM, Wigston Z, Laws P, et al. Rapid efficacy of anifrolumab across multiple subtypes of recalcitrant cutaneous lupus erythematosus parallels changes in discrete subsets of blood transcriptomic and cellular biomarkers. Br J Dermatol. 2023 Mar 22;189(2):210–218. doi: 10.1093/bjd/ljad089
   PubMed Web of Science ®Google Scholar
• Furie R, Werth VP, Merola JF, et al. Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus. J Clin Invest. 2019 Mar 1;129(3):1359–1371. doi: 10.1172/JCI124466.
   PubMed Web of Science ®Google Scholar
• Furie RA, van Vollenhoven RF, Kalunian K, et al. Trial of anti-BDCA2 antibody litifilimab for systemic lupus erythematosus. N Engl J Med. 2022 Sep 8;387(10):894–904. doi: 10.1056/NEJMoa2118025.
   PubMed Web of Science ®Google Scholar
• Khamashta M, Merrill JT, Werth VP, et al. Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016 Nov;75(11):1909–1916.10.1136/annrheumdis-2015-208562
   PubMed Web of Science ®Google Scholar
• Houssiau FA, Thanou A, Mazur M, et al. IFN-α kinoid in systemic lupus erythematosus: results from a phase IIb, randomised, placebo-controlled study. Ann Rheum Dis. 2020 Mar;79(3):347–355.10.1136/annrheumdis-2019-216379
   PubMed Web of Science ®Google Scholar
• Kalunian KC, Merrill JT, Maciuca R, et al. A phase II study of the efficacy and safety of rontalizumab (rhuMab interferon-α) in patients with systemic lupus erythematosus (ROSE). Ann Rheum Dis. 2016 Jan;75(1):196–202.10.1136/annrheumdis-2014-206090
   PubMed Web of Science ®Google Scholar
• Morand E, Pike M, Merrill JT, et al. Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: a phase II, randomized, double-blind, placebo-controlled trial. Arthritis & Rheumat. 2023 Feb;75(2):242–252. doi: 10.1002/art.42391.
   PubMed Web of Science ®Google Scholar
• Morand EF, Vital EM, Petri M, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I). Lancet. 2023 Mar 25;401(10381):1001–1010. doi: 10.1016/S0140-6736(22)02607-1
   PubMedGoogle Scholar
• Petri M, Bruce IN, Dörner T, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II). Lancet. 2023 Mar 25;401(10381):1011–1019. doi: 10.1016/S0140-6736(22)02546-6
   PubMedGoogle Scholar
• Wallace DJ, Furie RA, Tanaka Y, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2018 Jul 21;392(10143):222–231. doi: 10.1016/S0140-6736(18)31363-1
   PubMed Web of Science ®Google Scholar
• Alsukait S, Learned C, Rosmarin D. Open-label phase 2 Pilot study of oral Tofacitinib in adult subjects with discoid lupus erythematosus (DLE). J Drugs Dermatol. 2023 Apr 1;22(4):425–427.
   PubMedGoogle Scholar
• Werth VP, Fleischmann R, Robern M, et al. Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study. Rheumatology (Oxford). 2022 May 30;61(6):2413–2423. doi: 10.1093/rheumatology/keab685
   PubMed Web of Science ®Google Scholar
• Park JJ, Little AJ, Vesely MD. Treatment of cutaneous lupus with topical ruxolitinib cream. JAAD Case Rep. 2022 Oct;28:133–135. doi: 10.1016/j.jdcr.2022.08.038
   PubMedGoogle Scholar
• Klaeschen AS, Wolf D, Brossart P, et al. JAK inhibitor ruxolitinib inhibits the expression of cytokines characteristic of cutaneous lupus erythematosus. Exp Dermatol. 2017 Aug;26(8):728–730. 10.1111/exd.13253
   PubMed Web of Science ®Google Scholar
• Yusof MYM, Wittmann M, Fernandez C, et al. 47 Targeted therapy using intradermal injection of etanercept for remission induction in discoid lupus erythematosus (TARGET-DLE): results from a proof-of-concept phase II trial. Lupus Science & Medicine. 2019;6(Suppl 1):A34–A35.
   Google Scholar
• van Vollenhoven RF, Hahn BH, Tsokos GC, et al. Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study. Lancet. 2018 Oct 13;392(10155):1330–1339.10.1016/S0140-6736(18)32167-6
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Kalunian KC, Dörner T, et al. Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus. Ann Rheum Dis. 2022 Jul 7;81(11):1556–1563. 10.1136/ard-2022-222858
   PubMed Web of Science ®Google Scholar
• Furie RA, Bruce IN, Dörner T, et al. Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus. Rheumatology (Oxford). 2021 Nov 3;60(11):5397–5407. doi: 10.1093/rheumatology/keab381
   PubMed Web of Science ®Google Scholar
• Merrill JS, Duchesne D, Nowak M, et al. An anti-CD28 domain antibody, Lulizumab, in systemic lupus erythematosus: results of a phase II study [abstract]. Arthritis & Rheumat. 2018;70:1088.
   Web of Science ®Google Scholar
• Lipsky PE, Vollenhoven RV, Dörner T, et al. Biological impact of iberdomide in patients with active systemic lupus erythematosus. Ann Rheum Dis. 2022 Apr 27;81(8):1136–1142. doi: 10.1136/annrheumdis-2022-222212.
   PubMed Web of Science ®Google Scholar
• Furie RA, Hough DR, Gaudy A, et al. Iberdomide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled, ascending-dose, phase 2a study. Lupus Sci Med. 2022 Feb;9(1). e000581 10.1136/lupus-2021-000581
   PubMed Web of Science ®Google Scholar
• Merrill JT, Werth VP, Furie R, et al. Phase 2 trial of Iberdomide in systemic lupus erythematosus. N Engl J Med. 2022 Mar 17;386(11):1034–1045. doi: 10.1056/NEJMoa2106535
   PubMed Web of Science ®Google Scholar
• Werth V, Merrill J, Furie R, et al. OP0132 EFFECT of IBERDOMIDE on CUTANEOUS MANIFESTATIONS in SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS of a 24-WEEK, PLACEBO-CONTROLLED, PHASE 2 STUDY. Ann Rheumatic Dis. 2021;80(Suppl 1):76–77. doi: 10.1136/annrheumdis-2021-eular.2181
   Google Scholar
• Isenberg D, Furie R, Jones NS, et al. Efficacy, safety, and pharmacodynamic effects of the Bruton’s tyrosine kinase inhibitor Fenebrutinib (GDC-0853) in systemic lupus erythematosus: results of a phase II, randomized, double-blind, placebo-controlled trial. Arthritis & rheumat. 2021 Oct;73(10):1835–1846. 10.1002/art.41811
   PubMed Web of Science ®Google Scholar
• Luijten KM, Tekstra J, Bijlsma JW, et al. The systemic lupus erythematosus Responder index (SRI); a new SLE disease activity assessment. Autoimmun Rev. 2012 Mar;11(5):326–329. 10.1016/j.autrev.2011.06.011
   PubMed Web of Science ®Google Scholar
• Murphy CL, Yee CS, Gordon C, et al. From BILAG to BILAG-based combined lupus assessment-30 years on. Rheumatology (Oxford). 2016 Aug;55(8):1357–1363. 10.1093/rheumatology/kev387
   PubMed Web of Science ®Google Scholar
• Chakka S, Krain RL, Concha JSS, et al. The CLASI, a validated tool for the evaluation of skin disease in lupus erythematosus: a narrative review. Ann Transl Med. 2021 Mar;9(5):431. doi: 10.21037/atm-20-5048.
   PubMed Web of Science ®Google Scholar
• Langley RG, Feldman SR, Nyirady J, et al. The 5-point Investigator’s Global Assessment (IGA) scale: a modified tool for evaluating plaque psoriasis severity in clinical trials. J DermatolTreat. 2015 Feb;26(1):23–31. 10.3109/09546634.2013.865009
   Google Scholar
• Simpson E, Bissonnette R, Eichenfield LF, et al. The validated Investigator Global Assessment for atopic dermatitis (vIGA-AD): the development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis. J Am Acad Dermatol. 2020 Sep;83(3):839–846. 10.1016/j.jaad.2020.04.104
   PubMed Web of Science ®Google Scholar